Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on inflammation and immunology therapies and the operation of a growing boutique contract development and manufacturing business, announced that Chief Executive Officer Amir Reichman will co-lead a biopharma manufacturing roundtable during HealthIL Week 2026. The session is being organized by the Manufacturers Association of Israel and will bring together leaders from across the life sciences and manufacturing sectors.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
The roundtable, titled Biopharma Manufacturing in Israel Capabilities Gaps and Scale, is scheduled to take place on January 19, 2026 at Expo Tel Aviv. The discussion will be led jointly by Reichman and senior representatives from the Manufacturers Association of Israel and is designed to encourage an open and practical exchange on the current state of biopharma manufacturing in the country.
The session was convened at the request of the Manufacturers Association to support a realistic and data driven assessment of Israel’s biopharmaceutical development and manufacturing environment. Particular attention will be given to early stage development, chemistry manufacturing and controls activities, and clinical manufacturing capabilities across the full development lifecycle.
Discussions will focus on the availability of laboratory infrastructure, analytical and CMC expertise, and access to good manufacturing practice facilities for clinical supply. These elements are viewed as critical for efficient development timelines, regulatory preparedness, and informed investment decisions within the biopharma sector.
Health Technology Insights: Connecticut HIE Adopts PIQXL Gateway to Boost Data Quality
Participants will also examine Israel’s readiness to support later stage and commercial manufacturing. Topics will include the role of local and international CDMOs, the breadth of existing manufacturing capabilities, identified structural limitations, and opportunities for collaboration across the ecosystem.
The roundtable will additionally address global trends influencing biopharma manufacturing, such as the growing complexity of biologic therapies, changing regulatory expectations, and increased dependence on specialized manufacturing partners. Participants will explore how national capabilities may need to evolve over the next decade to remain competitive on a global scale.
Reichman said the Manufacturers Association plays a vital role in shaping Israel’s industrial future and that the goal of the roundtable is to take a clear and practical look at whether the country has the infrastructure needed to support biopharma companies from early clinical development through later stages. He added that the discussion is intended to identify concrete steps that can strengthen the foundation of the ecosystem.
Expected participants include representatives from government and public agencies, Israeli and international biopharma manufacturers and CDMOs, multinational pharmaceutical companies, biotechnology firms with clinical and commercial experience, and investors with direct exposure to manufacturing and development risk.
HealthIL Week is Israel’s leading international healthcare innovation conference and brings together stakeholders from industry, academia, government, and the investment community to address key challenges shaping the future of healthcare and life sciences.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
